ClinicalTrials.gg
RecruitingNCT07574697Updated May 8, 2026

AIC Genotyping Study

An observational study in Cardiomyopathy, Atrial Fibrillation (AF) and Genetic, sponsored by Barts & The London NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Barts & The London NHS Trust · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
299
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Cardiomyopathies with a site in United Kingdom — 19 open to participants now, 24 under way, 5 of them phase 3. Cardiomyopathies · United Kingdom.

Planned enrollment
12th of 25
299 · median 267
Started
2026
with 2 others
Observational
25 of 51
10 open now
Primary completion
2027-03
later than 8 of 23 live
Registered
49th of 51
by date
Lead sponsor
2 of 51
Barts & The London NHS Trust

Among the 51 studies in Cardiomyopathies with a site in United Kingdom, this one is the 12th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2026, is one of 25 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 49th registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

19 of the 51 studies in Cardiomyopathies with a site in United Kingdom are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Cardiomyopathies with a site in United Kingdom, or all of them as a file.
02

Study summary

To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive/negative controls

Read the detailed description

Atrial Fibrillation (AF) is the most common heart rhythm disorder affecting 1 in 3-5 adults over 45. Although most patients tolerate AF, in some people it can weaken the main pump of the heart (left ventricle), causing heart failure. It is not known why some people develop heart failure during AF and others do not. We propose that individual vulnerability is due to specific genetic abnormalities that do not cause problems until they develop AF. These genetic abnormalities have been identified in patients who develop heart failure with the onset of other stressors, such as alcohol or pregnancy.

Our study will identify 92 patients with AF-triggered heart failure, defined by having heart failure during AF but resolved after the AF was treated using a procedure called catheter ablation. We will measure how common these genetic variations are seen in patients with AF-triggered heart failure and compare them with 184 patients who have AF but don't develop heart failure (negative comparators) and 23 patients who do develop heart failure but do not recover after AF treatment (positive comparators).We shall only test for a limited number of clearly disease-causing genetic variants to ensure cost- effectiveness and minimise the risk of identifying genes of unclear significance.

If we find a genetic association, doctors could: (1) identify patients more likely to develop weakness before the AF becomes persistent, (2) fast-track at-risk patients for catheter ablation treatment, (3) offer family screening where appropriate, and (4) avoid unnecessary testing in low-risk patients. This would directly improve care for people in East London and beyond by personalising AF treatment and preventing avoidable heart failure.

03

Conditions studied

  • Cardiomyopathy
  • Atrial Fibrillation (AF)
  • Genetic

Keywords

  • prospective
  • case-controlled
  • genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is patients with a diagnosis of persistent AF who have undergone AF CA. Their LVEF at baseline and after CA in Sinus rhythm will determine eligibility. Barts Heart Centre, based at St Bartholomew's Hospital is a tertiary referral centre for cardiac electrophysiology with established expertise in AF CA. This will be the single study site. The team performed approximately 1300 index procedure AF CAs in 2018. Referral for AF CA to Barts Heart Centre is through a 'hub and spoke' arrhythmia service delivery model with its surrounding hospitals. Patients will be referred to the CRF for screening from the Electrophysiology out-patients clinic alongside the referral for AF CA. Vulnerable groups shall be excluded from this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

AIC (Cases):

  • Age ≥18
  • Persistent AF before index catheter ablation or cardioversion
  • ≤40% during rate-controlled (resting HR \<100bpm, mean HR on 24-hour Holter \<100bpm) AF prior to index catheter ablation or cardioversion
  • LVEF normalisation (LVEF ≥55%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation), and with no new introduction of any new or increased dose of heart failure guideline-directed medical therapy (GDMT) (renin-angiotensin-aldosterone system inhibitors (RAASi), Sodium Glucose Co-transporter 2 (SLGT2) inhibitors, increased dose of beta-blocker (BB), mineralocorticoid receptor antagonist (MRA))

AF-pEF (Negative controls):

  • Age ≥18
  • Persistent AF before index catheter ablation or cardioversion
  • LVEF ≥55% during rate-controlled (resting HR \<100bpm) AF. AIC-genotyping study, v1.7, 27.01.26 Page 13 of 28

AF/HF non-responders (Positive controls)

  • Age ≥18
  • Persistent AF before index catheter ablation or cardioversion
  • LVEF ≤40% during rate-controlled (resting HR \<100bpm) AF before index catheter ablation or cardioversion.
  • Persistent LVSD (LVEF ≤40%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation) and with no change in heart failure GDMT (RAASi, SGLT2 inhibitors, increased dose of BB, MRA).

Exclusion criteria

EXCLUSION:

AIC (Cases).

  • No alternative cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy
  • Any pregnancy during AF or in the 12 months preceding LVSD onset.
  • Alcohol intake >21 units/week
  • Any history of cardiotoxic chemotherapy

AF-pEF (Negative controls)

  • No known cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy).
  • Any pregnancy during AF or in the 12 months preceding LVSD onset.
  • Alcohol intake >21 units/week.
  • Any history of cardiotoxic chemotherapy.

AF/HF non-responders (Positive controls)

  • No alternative cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy).
  • Any pregnancy during AF or in the 12 months preceding LVSD onset.
  • Alcohol intake >21 units/week.
  • Any history of cardiotoxic chemotherapy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
299 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • AF induced Cardiomyopathy (Cases)

    Patients with LVSD during rate-controlled, persistent AF who improve their LVEF after sustained SR is achieved using catheter ablation or cardioversion.

  • AF-preserved EF (Negative controls)

    Patients without LVSD during rate-controlled, persistent AF

  • AF/HF non-responders (Positive controls)

    Patients with LVSD during rate-controlled, persistent AF who do not significantly improve their LVEF after sustained SR is achieved using catheter ablation or cardioversion.

06

What researchers measure

Primary outcomes

  1. DCM gene prevalence relative to negative control

    Group difference between AIC vs AF-pEF in P/LP prevalence from DCM panel

    Time frame: On day of baseline testing (1 day)

Secondary outcomes

  1. DCM gene prevalence relative to positive control

    Group difference between AIC vs AF/HF non-responders in P/LP prevalence.

    Time frame: On day of baseline testing (1 day)

Other outcomes

  1. Genotype-recovery time association

    Time from durable SR to LVEF normalisation: by genotype (TTNtv; any P/LP): HR from Cox models. Change in LVEF (post-SR minus pre-SR) by genotype: β from linear regression. Rapid recovery proportion (normalisation ≤90 days) by genotype

    Time frame: 12 months post-ablation time-point (independent of study enrolment date)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 119 non-industry observational studies under Cardiomyopathies, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 34. This study's planned 12 months is below that.

Counting every sponsor, half of 141 studies reached it within 83 months; a quarter within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 8, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
May 31, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07574697
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Mar 25, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Nikhil Ahluwalia, MBBS, PhD
Contact
nikhil.ahluwalia@nhs.net
+44(0) 20 3465 5398
Shohreh Honarbakhsh, MBBS, PhD
principal investigator · Queen Mary University of London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion